FDA Clears Provant Therapy System for Use by Patients with Metallic Implants

Clinicians can now treat post-op pain from joint replacements and spinal fusions

January 2014 Newsletter

Each year about 1.1 million patients have hip, knee, shoulder and elbow replacements, 350,000 have a spinal fusion, and 600,000 require internal fixation. Substantial pain following surgery is prevalent; for example, 32% of knee replacement patients experience ongoing pain. FDA has now approved the use of the Regenesis Provant for patients with metallic implants in the area of treatment. This allows many more patients to benefit from Provant's post-op pain relief.

Provant uses pulsed electromagnetic energy to facilitate reduction of the pain and edema associated with post-operative, superficial soft tissues. Provant relieves pain two ways: through anti-nociceptive analgesia by inducing endogenous opioids, and by regulating inflammatory mediators. To learn more, please contact your local Regenesis representative, or visit www.regenesisbio.com

Sincerely,

Richard A. Isenberg MD

Richard Isenberg, MD
Vice President, Clinical and Regulatory Affairs